Protagonist Therapeutics (PTGX) EBT (2015 - 2026)

Protagonist Therapeutics has reported EBT for 12 years, with the latest figure at $2.3 million in Q1 2026.

• Quarterly EBT rose 119.57% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$115.4 million (down 302.21% YoY) and the FY2025 annual result came in at -$129.3 million, down 146.29% from the prior year.
• EBT grew to $2.3 million in Q1 2026 per PTGX's latest filing, from -$43.7 million in the prior quarter.
• Over five years, EBT peaked at $210.7 million in Q1 2024 and troughed at -$66.9 million in Q1 2022.
• A 5-year average of -$6.2 million and a median of -$33.7 million in 2023 frame the typical range for EBT.
• The sharpest annual moves came in 2022 and 2024: EBT tumbled 178.95% in 2022, then surged 724.66% in 2024.
• Over 5 years, EBT stood at -$34.9 million in 2022, then jumped by 178.23% to $27.3 million in 2023, then soared by 388.88% to $133.6 million in 2024, then plunged by 132.71% to -$43.7 million in 2025, then jumped by 105.22% to $2.3 million in 2026.
• According to Business Quant data, EBT over the past three periods registered $2.3 million, -$43.7 million, and -$39.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.